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Abstract
Angiogenesis represents a form of neovascularisation of exceptional importance in numerous pathological
conditions including stroke. In this context it is directly related to neuroregeneration which is seen in close proxi-
mity. However, numerous experimental data have been drawn from studies that have ignored the age criterion.
This is extremely important as angiogenesis is different in young versus old subjects. Extrapolating data obtained
from studies performed in young subjects or “in vitro” to old-age patients could lead to inexact conclusions since
the dynamics of angiogenesis is age-dependent.
The current review covers the key features of brain senescence including morphological and functional changes
related to the brain parenchyma, its vascular network and blood flow which could possibly influence the process
of angiogenesis. This is followed by a description of post-stroke angiogenesis and its relationship to neuroregen-
eration and its modulation by vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF 1), the
most important factors active in old brain after ischemic injury.
Introduction
Neovascularization represents a crucial phenomenon of
paramount importance for the clinical outcome in var-
ious pathological conditions including cancer, myocar-
dial infarction and cerebral stroke. Until not too long
ago, it was thought that CNS damage induced by stroke
is associated with irreversible tissue damage. However,
recently, experimental data indicates that this is not the
case and neuroregeneration is observed after stroke
[1,2]. Interestingly, it appears that post-stroke neurore-
generation depends significantly on neovascularization
which is encountered in several flavors: vasculogenesis,
angiogenesis and arteriogenesis [3]. Vasculogenesis
represents the embryological development of the blood
vessels from angioblastic precursors and it has been
recently described in patients after stroke [4]. Although,
the extent to which vasculogenesis modulates post-
stroke neuroregeneration is not known, the link between
this process and angiogenesis is represented by VEGF
and its receptor, which modulate transformation of
immature precursor structures into mature capillaries
[5]. Arteriogenesis is the growth of collateral arteries
from pre-existing arterioles after blockage of the main
artery. Compared with angiogenesis it does not require
a hypoxic environment, and is typically activated by
increased pressure and stress, such as that caused by
occluded and partially occluded vessels [6]. The contri-
bution of this process to neuroregeneration is unknown,
however, numerous studies have reported that angiogen-
esis or formation of new capillaries from pre-existent
vessels is closely related to neuroregeneration. After
stroke, primordial cells capable to differentiate into
functional neurons have been identified in the immedi-
ate vicinity of newly formed capillaries [7]. Therefore, it
was claimed that this process can be regarded as a neu-
rorestorative event promoting formation of new neurons
from adult brain’s own neural stem cells (NSC) [8,9].
Although factors such as matrix metalloproteinase-2
(MMP-2), matrix metalloproteinase-9 (MMP-9), tissue
inhibitor of matrix metalloproteinase 1 (TIMP-1), Hepa-
tocyte growth factor (HGF-alpha), monocyte chemo-
attractant protein 1 (MCP-1) are increased after
ischemic stroke the most important seems to be VEGF
and its receptor which are increased in the periphery of
the ischemic zone at 3 hours after stroke [10,11].
Although, a great deal of research has been performed,
it seems that there are significant differences in the
angiogenesis encountered in old subjects compared with
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young ones, including the extent of this process and the
factors that may modulate it during different develop-
mental stages. However, since angiogenesis depends on
the pre-existing vascular network it is very important to
understand if there is any relationship between what is
happening with the brain per se and its cerebral blood
vessels during senescence and the extent and/or modu-
lation of post-stroke angiogenesis in this context.
The current review will highlight the most salient
points related to the senescent brain and its vasculature,
and then based on the published data we will review the
factors which unequivocally modulate angiogenesis only
in elderly subjects. This is necessary since ischemic
stroke is mostly described in old age and extrapolating
results obtained “in vitro” or from young subjects could
lead to erroneous conclusions.
CNS aging process: pivotal points
Normal aging is associated with a cognitive decline and
understanding the related mechanisms remains a central
challenge in neuroscience. Moreover, it is currently
poorly understood how the CNS morphological changes
associated with old age would affect the vascular net-
work and ultimately post-stroke angiogenesis.
Morphological and physiological studies have tried to
explain the decline in cognitive function associated with
old age based on anatomical changes. More than fifty
years ago, it was suggested that weight reduction in the
senescent brain could be explained by a significant
reduction in the neurons [12]. Recently, MRI studies
conducted in healthy volunteers have revealed that brain
weight loss may affect with predilection only some
regions of the brain such as hippocampus or the pre-
frontal, frontal or enthorinal cortex and the loss of
white matter is greater than the decrease in grey matter
[13,14]. Other authors have recorded a reduction of the
whole limbic system grey matter in healthy elderly [15].
Between 30 and 90 years of age, there is an overall
decrease in weight of 14% recorded in the cerebral cortex
associated with a 35% reduction in the hippocampus, and
a 26% weight loss in the cerebral white matter [13]. How-
ever, it is still debatable if the changes seen in hippocam-
pus are related to “normal” senescence as other studies
have suggested that cell death and a decline in weight
occurring in this region is not normally observed [16,17].
Studies in mice have indicated that aging may reduce
both overall neural cell proliferation as well as the devel-
opmental pathway followed by proliferating cells in the
brain, leading to fewer mature neurons replacing those
lost to age or damage [18].
Regarding the vasculature, although earlier studies
have shown no difference or even an increase in the cer-
ebral arteriolar network in old versus young subjects,
the current opinion is that old age is characterized by a
significant decrease in density of vessels supplying the
cerebral cortex compared with young controls as well as
morphological changes of the remaining vessels [19-22].
More recently, Amenta et al (1995) have reported that
the capillary network is significantly decreased in Wistar
rats of 27 and 24 months versus young 12 month-old
subjects [23]. Therefore, it seems unequivocal that aging
is associated with a significant decrease in superficial
cortical vessels which according to some authors, could
be induced by an age-related decrease in growth hor-
mone and insulin-like growth factor 1 [21]. However,
growth hormone treatment administered to aged ani-
mals for 6 weeks did not alter hippocampal capillary
density and did not ameliorate the age-related deficit in
angiogenesis. Therefore, the exact relationship between
growth hormone and angiogenesis remains to be eluci-
dated. However, aged animals demonstrate a significant
impairment in hypoxia-induced capillary angiogenesis
compared to young animals [24].
Regarding the structural alterations of the vessels,
significant aging-related microvascular degeneration
was encountered especially in the periventricular white
matter [25]. Also, in elderly rat subjects there is a
decrease in smooth muscle and elastin in parallel with
an increase in collagens which impair distension [26].
Senescent arterioles present with alterations in capil-
lary endothelial cells including a thickened basement
membrane, abnormal inclusions and abnormalities of
the astrocytic endfeet [27-29]. However, the mechan-
ism behind these changes remains poorly understood
although it is accepted that these ultrastructural altera-
tions could lead to a small leakage of blood in the par-
enchyma [30].
Regarding the cerebral blood flow in old-age, recent
data suggests that it decreases with advancing age
[31,32]. Previous studies have shown a direct correlation
between cerebral blood flow and vascular density [33]. It
seems that cerebral blood flow is modulated by circulat-
ing norepinephrine, NO and sympathetic noradrenergic
innervations of cerebral arteries. The young subjects are
characterized by little noradrenergic innervations of cere-
bral arteries and weak cerebral vasoconstriction. These
innervations increase with age but decrease by middle-
age in a murine model. However, the norepinephrine
evoked cerebral vasoconstriction is stronger in mature
and middle-aged rats and although the NO would limit
the vasoconstriction, this is followed subsequently by a
drop in cerebral blood flow [34]. Interestingly, previous
studies conducted in a murine model suggest that a
decreased blood flow is paralleled by a decline in cogni-
tive tasks [35-37]. Therefore, one may speculate that a
decrease in blood flow would lead to a decreased ener-
getic support for neurons which complicates the func-
tional profile of the aging brain including the post-stroke
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angiogenesis. The most important changes in vasculariza-
tion with ageing in the brain are represented in Figure 1.
In addition, old age is characterized by the presence of
several pathological entities affecting the vasculature.
Cerebral atherosclerosis and small vessel disease are
characterized by plasma protein infusion into the vessel
wall, accumulation of foamy cells, and fibrosis while
another relatively common condition, amyloid angiopa-
thy, is associated with deposition of amyloid in the ves-
sel wall [38]. Therefore, since the functionality of the
nervous system is dependent upon a well developed and
maintained blood supply, we could speculate that any
morphological and physiological aging-related changes
in the microvasculature could affect neuronal integrity.
Related to Alzheimer’s disease which is also seen in old-
age patient, clinical studies have indicated that educa-
tion has a protective effect. This has been attributed to
a “reservoir effect”, with the loss of neurons compen-
sated for by more extensive neural connections. Given
the links between dementias and reduced blood flow to
the brain, it is possible that at least some of this effect
may be mediated through a more developed vascular
system, or potentially by retention of more juvenile
modes of angiogenic response due to extended learning.
This would make some sense in the context of experi-
mental studies conducted in rats, which show that
angiogenesis occurs in the adult rat cerebellum after
physical exercise and motor skills learning [39].
A brief account of central nervous system “normal”
senescence and the pathological changes associated with
it is presented in Figure 2.
Post-stroke angiogenesis
One may define the process of angiogenesis as sprout-
ing of new capillaries from pre-existent vessels. As a
result of this ongoing process, the newly formed plexus
increases gradually in size and remodels into a vascular
network which ultimately forms endothelial-cell (EC)
channels in close proximity with pericytes and smooth
muscle cells. This cellular composition is of paramount
importance for functionality of the new vessels includ-
ing the strength of the wall and regulation of the
blood flow [40]. Interestingly after stroke, neuroblasts
which will further differentiate into fully functional
neurons were identified in close proximity around the
immature newly created vascular network [41]. This
would suggest that neurogenesis depends on a preli-
minary angiogenesis.
Post-stroke cerebral angiogenesis represents an essen-
tial event of crucial importance that unfortunately is not
completely understood. Several factors such as: beta-
Figure 1 Aging produces a number of physical and
biochemical changes in the vascular system that contribute to
the age related degeneration of the brain. At the macroscopic
level, reduced vessel density is observed in aging brains, leading to
an overall reduced blood flow and oxygenation into brain tissue,
that may be further exacerbated by pathological factors. At the
cellular level, the vessel walls begin to reduce the expression of
growth factor receptors, leading to reduced ability to respond to
growth and survival factors. Vessels also begin to lose smooth
muscle cells, reducing the capacity of vessels to maintain blood
pressure, reducing oxygenation in certain circumstances. Aging also
leads to a reduced expression of growth and survival factors into
the bloodstream, further reducing the survival capacity of vessel
lining cells. Many of these factors combine to lead to vessel
degeneration, where reduced flow rates, reduced receptor
expression and reduced growth factors lead to narrowing of vessels,
further reducing flow and reducing vessel diameter, to a point
where red blood cells can no longer flow through vessels, leading
to loss of oxygenation of tissues and further degeneration into a
string vessel state.
Figure 2 Central nervous system “normal” senescence and
pathological changes. Aging in the CNS involves a range of
diverse changes, including those associated with normal senescence
and present in all surveyed brains. These include reduced weight of
brain as a result of decreased neuron counts, as well as reduced
vessel density and integrity in the vasculature. More pathological
changes include atherosclerosis, small vessel disease and amyloid
proteins. These combine with normal vaso- constriction and dilation
effects to alter overall cerebral blood flow.
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catenin, matrix metalloproteinase-2 (MMP-2) matrix
metalloproteinase-9 (MMP-9), tissue inhibitor of matrix
metalloproteinase-1 (TIMP-1), hepatocyte growth fac-
tor-alpha (HGF-alpha), monocyte chemoatractant pro-
tein-1 (MCP-1) and Angiopoietin1/Tie-2 as well as c-kit
are increased after ischemic stroke [42].
Beta-catenin is a member of the cadherin complex and
a signaling protein in the Wnt pathway. It has been
linked to the proliferation of neuronal progenitor cells
in stroke induced neurogenesis [43]. In stroke, MCP-1 is
thought to be one of the major factors influencing infil-
tration of the infarct region by leukocytes and is linked
with increased volume of the infarct and increased
damage [44]. Experimental data suggests that in rats
with middle cerebral artery occlusion the lack of MCP-1
or its receptor CCR-2 is associated with a significant
decrease in the number of migrating neuroblasts reach-
ing the ischemic area. This affects the neural regenera-
tion negatively [45]
The MMP family participates in the breakdown of
various extracellular matrix proteins, and is associated
with wound healing and tissue remodeling. In stroke,
the MMPs have been implicated in the breakdown of
the blood-brain barrier and increased damage [46-51].
Different MMPs are expressed in different conditions
and at different times following stroke, with MMP-2
being amongst the first activated, followed by MMP-9 in
later stages of inflammation and repair [52].
Research conducted in murines recently, indicates that
the major source of MMP-9 in cerebral ischemia is
represented by bone-marrow derived cells [53]. Remark-
ably, MMP-9 promotes neural progenitor cells migration
towards the ischemic brain area in a model of transgenic
mice after photothrombotic ischemia [54].
Clinical studies conducted in patients with various
types of stroke have revealed that MMP-2 gene is asso-
ciated with the development of lacunar stroke [55].
However, it rises in parallel with MMP-9 in a rat model
of transient cerebral ischemia [56]. It seems that MMP-
2 and MMP-9 expression is decreased after minocycline
administration in rats with induced cerebral ischemia.
This is associated with a decreased incidence of hemor-
rhage and decreased degradation of collagen IV and
laminin alpha in the brain. Overall, the neurological out-
come in cerebral ischemia is improved by minocycline
through MMP-2 and MMP-9 downregulation [57]. In
patients with severe stroke both MMP-2 and MMP-9
have a strong association with edema formation and
midline shift [58].
The TIMPs are inhibitors of the MMPs and their
induced overexpression has been shown to aid in reduc-
tion of infarct size and recovery in a rat model of
ischemia [59].
HGF-alpha is known to induce angiogenesis and has
been seen to increase in expression following MCAO in
mouse models, though a high serum level of the protein
was found to be an independent risk factor for stroke in
postmenopausal women [60,61].
Experimental evidence suggests that angiopoietin 1
(Ang1) and its endothelial kinase 2 (Tie2) are up-regu-
lated after stroke by a nitric oxide donor and subse-
quently promote neuroblast cell migration towards the
ischemic area [62]. Inceased levels of Ang1/Tie2 have
been recorded in ischemic stroke models after simvasta-
tin treatment and infusion of bone marrow stromal
cells. Both treatments result ultimately in vascular stabi-
lization and angiogenesis [63,64].
The above mentioned factors are involved in events
of paramount importance namely, endothelial cell
migration, tissue remodeling, differentiation and tube-
formation, vessel stabilization and stem cell homing
mechanisms in areas of revascularization. Therefore, we
could speculate that therapy modulating their expression
and the activity of these factors could help the recovery
and restoration of the damage after stroke [42]. Several
of these factors are also associated with arteriogenesis,
and it is possible that multiple systems may come into
play after stroke, depending on its severity, or that there
is a certain amount of cross-talk between the angiogenic
and arteriogenic systems. A concise summary of the
possible molecular mechanisms and general effects of
angiogenesis after stroke in elderly subjects is presented
in Figure 3.
Figure 3 Possible molecular mechanisms and general effects of
angiogenesis after stroke in elderly subjects. Stroke causes
ischemic damage to the brain, activating angiogeneic mechanisms
in response. The degree of response is modulated by changes to
the neural and vascular response caused by aging, but the general
response remains similar. Growth factors, tissue remodeling and
inflammatory proteins are released, leading to the building of new,
well developed endothelial channels, which aid recovery.
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However, at the present time, we do not have any
information on the dynamics of the above mentioned
factors with aging. Since ischemic stroke is most likely
to be encountered in elderly, any possible therapy
should be verified in the context of aging. This means
taking into consideration the level of the targeted factors
in old age, the ability of the vascular and support sys-
tems to respond to them and the integrity of down-
stream gene expression in the targeted pathways. To
date, only VEGF and IGF-1 have been evaluated as
modulators of neovascularisation in old subjects.
Post-stroke angiogenesis modulators in old age subjects
VEGF and its receptors
Without any doubt, vascular endothelial growth factor
(VEGF) is the most important promoter of angiogenesis
secreted by endothelial cells and pericytes [65].
Recent research evaluating the role of remnants of
capillaries the so-called string vessels, indicates that
VEGF represents an endothelial cells survival factor.
String vessels have been described in ischemic condi-
tions but also in normal human brains. They represent
capillaries that have lost their endothelial cells. It seems
that their presence is associated with an age-related
decline in VEGF [66].
One of essential aspects related to VEGF is repre-
sented by the fact that neurogenesis takes place near
cerebral capillaries where both VEGF and angiogenesis
are up-regulated. Therefore, it is believed that that
VEGF links neurogenesis and angiogenesis [67-69].
After ischemic stroke, VEGF is detected on microglial
cells and macrophages and also on capillaries within the
peri-ischemic zone, where a pro-angiogenic effect may
be identified. Notably both VEGF mRNA and one of its
receptors (VEGFR-1) are increased in the periphery of
the ischemic zone at 3 hours after stroke reaching a
peak after 24 h, and remaining detectable 7 days post
stroke [70]. Therefore, it was argued that an increased
production of VEGF and its receptor represent a physio-
logical response to ischemia which ultimately aims to
preserve and to restore the damaged nervous tissue,
consistent with the functions of the VEGF system in
other tissues.
Remarkably, experiments conducted in a murine
model of middle cerebral artery occlusion have indicated
that apoptosis of the neurons in the penumbra is signifi-
cantly depressed after the beginning of angiogenesis and
it appears that anti-apoptosis is achieved by VEGF dur-
ing angiogenesis via the induced expression of survivin
in endothelial cells [70,71].
Most importantly, the experimental data on VEGF has
been positively matched by clinical data. Neurons,
endothelial cells, and astrocytes in the penumbra from
patients that died after ischemic stroke are characterized
by an increased expression of VEGF compared with
contralateral areas [72]. Moreover, in patients with acute
ischemic stroke serial measurements pointed towards an
increased serum level of VEGF, which correlated very
well with infarct volume and clinical disability [73].
In atherosclerotic lesions VEGF is induced by C-reac-
tive protein (CRP) and significant time-dependent
up-regulation of VEGF-A mRNA expression and its pro-
tein was recorded in monocytes after treatment with
CRP. It seems that the most plausible mechanism for this
is represented by the activation of a PI3-kinase and an
extracellular signal regulated kinase (ERK) [74,75]. Also,
VEGF modulates hypoxia-induced CNS angiogenesis
[76,77]. In middle cerebral artery occlusion (MCAO)
experiments, the induced hypoxia represents a signal for
activation of hypoxia-inducible factors which subse-
quently promote expression of VEGF and its receptor
genes [78]. However, as mentioned above, hypoxia-indu-
cible angiogenesis is decreased with aging [24]. Therefore
one may conclude that VEGF and/or its receptors are
down-regulated with aging, and/or that long term effects,
such as promoter methylation retard the capacity of aged
cells to respond to pro-angiogenic signals brought on by
hypoxia. Interestingly, in selected areas of brain such as
the hippocampus there is a significant decrease of VEGF
between young and middle age animals. However, there
is no difference between middle age and elderly subjects
[65,79]. It appears that decreased hippocampal VEGF
concentration in middle age is related to numerous
changes in the cellular substrates for VEGF. These
abnormalities include reduced proliferation of endothelial
cells in capillaries and degeneration of endothelial
cells, especially in the vascular niche surrounding stem/
progenitor cells [67].
Recently, in vitro and in vivo studies conducted by
Emerich et al (2007) have shown that choroid plexus
epithelial cells from young subjects secrete more VEGF
and are metabolically more active than the same type of
cells from aged animals [80]. Moreover, transplantation
of choroid plexus epithelial cells from old subjects is sig-
nificantly less neuroprotective than the transplant of the
same type of cells from young rats [80]. In addition, the
angiogenic and neurogenic response to adeno-associated
viral vector-VEGF injections is decreased in the aged
mouse brain [81]. Brains from 24 month old mice, com-
pared to those of 3 and 12 month old mice, in the study
by Gao et al. showed reduced expression of VEGFR-2,
another VEGF receptor commonly associated with
angiogenic functions [81]. This may explain the reduced
angiogenic response seen in these brains. In addition,
the brains of 24 month old mice showed lower levels of
neuroprogenitor cells following stroke and VEGF stimu-
lation. Thus, it may be that reductions in VEGF receptor
expression, accumulation of senescence markers and
Petcu et al. Journal of Angiogenesis Research 2010, 2:26
http://www.jangiogenesis.com/content/2/1/26
Page 5 of 10
other metabolic changes in endothelial and neural cells
lead to reduced proliferative response.
Since the activity of other pro-angiogenic factors such
as placental growth factor (PLGF) and neuropilins (NP1
and NP2) is directly linked to the level of VEGF/VEGF
receptors, one may speculate that their level could also
be affected by the aging process [82-84]. However, no
studies have been specifically designed to evaluate these
factors in aged subjects.
A summary of the possible VEGF related mechanisms
of post-stroke angiogenesis in elderly subjects is repre-
sented in Figure 4.
Insulin-like growth factor I (IGF-1)
Experiments conducted on human tissue have shown
that increased levels of insulin-like growth factor I (IGF-
I) and vascular endothelial growth factor (VEGF) are
associated with neovascularization induced by retinal
ischemia [85].
Anderson et al (2002) have suggested that IGF-1
induces neurogenesis from adult-derived neural precur-
sors in vitro and has similar effects on the hippocampal
progenitor population in vivo [86]. Relatively recent
research has proved that insulin-like growth factor-I
(IGF-I) may regulate neurogenesis in the aging brain.
This experimental hypothesis has been derived from the
fact that IGF-1 influences neuronal production during
development and, similar to neurogenesis itself, it
decreases with old age. Lichtenwalner et al (2001) have
showed an age-dependent reduction in the number of
newly generated cells in the adult dentate subgranular
proliferative zone [87]. This was paralleled by a 60%
reduction in the differentiation of newborn cells into
neurons. Remarkably, restoration of IGF-I levels in
senescent rats significantly restored neurogenesis, with
an approximately three-fold increase in neuronal pro-
duction reported. Therefore, the authors suggest that
IGF-I may significantly modulate neurogenesis in aging
hippocampus and that an age-related decline in IGF-I-
dependent neurogenesis could contribute to age-related
cognitive changes [87].
Experimental studies conducted in murine models
have shown that vasculature and meninges are an
important source of IGF-1 for the brain and that expres-
sion continues throughout life. In addition, there are no
changes in IGF-1 gene expression with age but IGF-1
protein levels decrease suggesting that translational defi-
ciencies or deficits in the transport of IGF-1 through
the blood-brain barrier contribute to the decline in
brain IGF-1 with age. This would imply that aging is
correlated with significant changes in the IGF-1 axis
which cause the brain senescence itself [88].
As mentioned previously, the vascular density on the
surface of the cortex decreases with aging. This corre-
lates with low IGF-1 plasma levels, which would suggest
that IGF-1 has an important role in the decline of vas-
cular density associated with aging [21]. In the hippo-
campus, concentrations of IGF-1 decrease significantly
between young and middle aged experimental animals.
The drop in IGF-1 levels is also recorded in old-age
subjects. However, there is no significant difference
between IGF-1 levels recorded in middle-age and elderly
subjects [89].
Recent experimental research has revealed that both
local and serum IGF-1 modulate angiogenesis after
brain trauma. Low IGF-1 level impairs angiogenesis and
promotes vascular dysfunction [90]. These results con-
firm previous data from elderly patients with ischemic
stroke which have reported up-regulated levels of IGF-1
in the context of a well established angiogenesis [91].
Interestingly in a study conducted in elderly patients
with stroke, serum IGF-1 levels assessed within 24
hours of the onset of stroke were significantly lower
than levels in controls. Presumably these patients had
low levels of IGF-1 before stroke, though this has not
been established. However, low levels of IGF-1 were fre-
quently associated with death [92]. Other studies have
shown that high levels of IGF-1 before stroke are asso-
ciated with a larger ischemic area [92,93]. The authors
speculate that a high level of IGF-1 would increase the
susceptibility to ischemia produced by middle cerebral
artery occlusion. In this context the damage induced by
increased IGF-1 could be produced by activation of
MAPK [94]. Moreover in an experimental setting, IGF-1
is beneficial if given after ischemia but not before the
Figure 4 VEGF and post-stroke angiogenesis in elderly
subjects. Morphological and molecular changes lead to medial
cerebral artery occulsion and similar states that give rise to full
ischemic stroke. Both occulsion and outright stroke lead to
stimulation of VEGF release by affected cells, which drives the
expression of additional effector proteins, increases angiogenesis,
promotes cell survival and neurogenesis, leading to recovery. Aging
reduces the activation of certain responses, including HIF-1a and
the ability of cells to respond to VEGF through downregulation of
receptors, impairing repair and recovery.
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event [95-97]. Unfortunately, we do not have a clear
explanation of these facts yet, though it may be that
high levels of IGF-1 prior to stroke may reduce tissue
responsiveness afterwards, due to negative feedback
loops reducing expression of downstream signal recep-
tors. It is also possible that a high level of IGF-1 prior
to stroke may be indicative of substantial, but low-level
hypoxia in the tissue and that the already stressed neu-
rons are less likely to survive an ischemic event. Overall,
the role of IGF-1 in modulating angiogenesis and vascu-
lar development is still not completely elucidated.
Further research should take into consideration not only
the age of the subjects but also the dynamics of IGF-1
level before, during and after ischemic damage produced
by stroke.
Other growth factors and cellular studies
Although VEGF and IGF seem to be the main actors in
post stroke angiogenesis, there are a number of other
factors in play. As well as the relationship between gene
expression and age in the VEGF and IGF systems, simi-
lar relationships have been noted for fibroblast growth
factor (FGF) and transforming growth factor beta 1
(TGFb-1).
As for VEGF, expression of FGF is increased in the
area surrounding a stroke in human subjects [98].
In the rat and porcine models, however, an age speci-
fic reduction in FGF receptor expression and signaling
has been observed, and it seems likely that a similar loss
of expression is experienced in human brains [98-100].
Likewise, TGFb-1 is more highly expressed in the
immediate area around a stroke, but is not sufficiently
increased to affect measurements of concentration [73].
Studies in cell cultures have indicated that long term
cultured cells show reduced capacity to form tubes in
appropriate culture conditions, as well as increased mor-
phological heterogeneity [101]. Cell culture models of
older cells also show similar losses of VEGF expression
to those observed in older whole animals [79]. This
would indicate that in both in vivo and in vitro studies,
there are significant alterations in the behavior of aged
endothelial cells compared to younger ones.
In conclusion
Old age is associated with a variety of morphological,
physiological and metabolic features which may alter
recovery after stroke. These features combine normal
aging of brain with the ongoing processes of neurode-
generation and small vessel disease. These work in
synergy to reduce the capacity of both neural and vascu-
lar cells to respond to ischaemic insult, as well as com-
promising their maintenance and basic functions.
One of the most important changes is represented by
a decrease of the normal cerebral vascular network. This
may affect the ability of the old-age subjects to mount
an adequate pro-angiogenic response after an insult
such as stroke. VEGF/VEGFR and IGF-1 represent the
most important modulators of post ischemic angiogen-
esis. Research is showing that some of the changes to
the mechanisms behind these effects are similar in both
neural and vascular tissues. However, we cannot be sure
if the decrease in their level is due to morphological,
physiopathological or metabolic changes, or how these
may interact to contribute to the changes seen in the
aging brain and vasculature. The role and the promoters
of these factors are also incompletely understood, but
they may be related to age-associated loss of cellular
proliferative ability and increasing negative regulation by
cellular senescence markers. In addition, since ischemic
stroke is a pathological entity most likely encountered in
the elderly, future studies should evaluate any possible
therapeutic targets related to post ischemic stroke
angiogenesis only in aged animals or higher passage
in vitro systems. More research is also needed to fully
explain the mechanisms at work in the ischemic senes-
cent brain which may influence angiogenesis and/or the
final outcome of the subject. This is crucial not only to
understand the nature of stroke, but also to provide the
best therapeutic response with current methods and to
develop new treatment and, potentially, preventative
options.
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